Results 121 to 130 of about 8,156 (174)

Counting cases, conserving species: addressing highly pathogenic avian influenza in wildlife

Biological Reviews, EarlyView.
ABSTRACT Highly pathogenic avian influenza (HPAI) has become a critical threat to wildlife, shifting from a seasonal epizootic to a persistent, year‐round panzootic with global consequences. Here, we summarise the origin, evolutionary mechanisms, and expanding host range of the current H5N1 virus (clade 2.3.4.4b) and assess its impact on wildlife. Over
Ulrich Knief, Sandra Bouwhuis, Anja Globig, Anne Günther, Wouter Courtens   +4 more
wiley   +1 more source

Human Papillomavirus: Update in Bridging Basic Science to Clinical and Public Health Innovations. [PDF]

Health Sci Rep
Beygnejad F, Eslami N, Nejad KG, Kermanshahi AZ, Baghi HB.   +4 more
europepmc   +1 more source

Highly Potent Fluorogenic Ligands for Triplex DNA: 5‐Substituted 2‐(Naphthalen‐2‐yl)‐4H‐Chromen‐4‐Ones

Chemistry – A European Journal, EarlyView.
5‐Substituted 2‐(naphthalen‐2‐yl)‐4H‐chromen‐4‐ones are reported as a novel class of highly potent and selective triplex DNA ligands. These ligands induce triplex formation at submicromolar concentrations and inhibit enzymatic activity via ligand‐mediated triplex formation.
Nghia Tran, Landy Gu, Krege M. Christison, Kalee Thao, Liang Xue   +4 more
wiley   +1 more source

Disease burden and treatment patterns of paroxysmal nocturnal hemoglobinuria in Japan: a real-world survey. [PDF]

Int J Hematol
Sakurai M, Ueda Y, Obara N, Kroes M, Dochi T, Wiyani A, Balp MM, Somenzi O, Taylor Y, Kawaguchi T, Nishimura JI.   +10 more
europepmc   +1 more source

Dynamic Control of Nucleic Acids Self‐Assembly and Expression Using Photoswitches

Chemistry – A European Journal, EarlyView.
We review here the recent progress made in the design of molecular photoswitches, and highlight their implementation for the dynamic control over nucleic acids self‐assembly and expression. ABSTRACT Synthetic nucleic acids have become readily available and now constitute versatile building blocks in materials science—where they can be used to engineer ...
Noemí Nogal, Hugo Laigle, Maxime Mansy, Sébastien Ulrich, Mathieu Surin   +4 more
wiley   +1 more source

C3 mutations and poor pegcetacoplan response in paroxysmal nocturnal hemoglobinuria. [PDF]

Front Immunol
Rodríguez de Córdoba S, Reparaz Suevos A, González Sanz S, Fernández FJ, Vega MC, Varela EC, Lada Colunga A, Vallejo Llamas JC, Gonzalez-Rodríguez AP.   +8 more
europepmc   +1 more source

Analysis and Characterization of Kisspeptin and Its Analogues in Serum and Urine Samples by Liquid Chromatography–High‐Resolution Mass Spectrometry for Doping Control Purposes

Drug Testing and Analysis, EarlyView.
Sensitive LC‐HRMS methods were established for the detection of kisspeptin and its analogues in serum and urine, alongside their analytical and metabolic characterization. Stability studies were conducted in serum, plasma, and urine, highlighting the importance of appropriate sample handling for reliable anti‐doping analysis.
Sophia Krombholz, Linus Korsmeier, Andreas Thomas, Mario Thevis   +3 more
wiley   +1 more source

Population PK-PD Modeling of Danicopan Add-On Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria Treated With Ravulizumab or Eculizumab. [PDF]

CPT Pharmacometrics Syst Pharmacol
Chen J, Yang F, Li H, Pradhan R, Ortiz S.   +4 more
europepmc   +1 more source

Phase I Metabolism of Novel Phencyclidine Derivative 3‐Cl‐PCP: In Vitro Studies With Pooled Human Liver Microsomes and Investigation of a Post‐Mortem Case

Drug Testing and Analysis, EarlyView.
A fatal 3‐chloro‐phencyclidine (3‐Cl‐PCP) intoxication was investigated by analyzing postmortem samples and a pooled human liver microsomes assay. Tentative metabolite identification was performed by liquid chromatography‐quadrupole time‐of‐flight mass spectrometry (LC‐QTOF‐MS). Seven phase I metabolites were identified.
Johannes Kutzler, Tobias Veit, Thomas Keller, Volker Auwärter   +3 more
wiley   +1 more source

Complement profiling for treatment outcomes in pulmonary TB. [PDF]

Front Immunol
Pavan Kumar N, Nancy P A, Hissar S, Sivakumar S, Viswanathan V, Bethunaickan R, Kornfeld H, Babu S.   +7 more
europepmc   +1 more source